avelumab

Home
Ligands
avelumab

GtoPdb Ligand ID: 8735

Synonyms: Bavencio® | MSB-0010718C | MSB0010718C

avelumab is an approved drug (EMA & FDA (2017))

Comment: Avelumab is a programmed death-ligand 1 (PD-L1; CD274) blocking human IgG1 lambda monoclonal antibody . It is the first drug approved for the treatment of Merkel cell carcinoma (MCC).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.

No information available.

No information available.

Summary of Clinical Use
Avelumab was FDA approved in March 2017 (under the FDA's accelerated approval program), and by the EMA in August 2017. Both approvals are for the treament of Merkel cell carcinoma (MCC; a rare and aggressive type of skin cancer) in adults and children >12 years old. In May 2017, FDA accelerated approval was also granted for the treatment of locally advanced or metastatic urothelial carcinoma (that has progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy). It has been granted orphan status by the EMA (December 2016) for gastric cancer. Avelumab plus the receptor tyrosine kinase axitinib gained FDA approval as a first-line treatment for patients with advanced renal cell carcinoma in May 2019.

Summary of Clinical Use

Avelumab was FDA approved in March 2017 (under the FDA's accelerated approval program), and by the EMA in August 2017. Both approvals are for the treament of Merkel cell carcinoma (MCC; a rare and aggressive type of skin cancer) in adults and children >12 years old. In May 2017, FDA accelerated approval was also granted for the treatment of locally advanced or metastatic urothelial carcinoma (that has progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy). It has been granted orphan status by the EMA (December 2016) for gastric cancer. Avelumab plus the receptor tyrosine kinase axitinib gained FDA approval as a first-line treatment for patients with advanced renal cell carcinoma in May 2019.

Mechanism Of Action and Pharmacodynamic Effects
Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug's mechanism of action enables immune cells to detect and destroy tumour cells.

Mechanism Of Action and Pharmacodynamic Effects

Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug's mechanism of action enables immune cells to detect and destroy tumour cells.